Last Updated: June 11, 2026

IRINOTECAN Drug Patent Profile

Name: IRINOTECAN Drug Patent, Exclusivity, and Generic Launch Dataset
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Irinotecan, and what generic alternatives are available?

Irinotecan is a drug marketed by Accord Hlthcare, Actavis Totowa, Chartwell Rx, Cipla Ltd, Emcure Pharms Ltd, Epic Pharma Llc, Eugia Pharma, Fresenius Kabi Usa, Gland, Hengrui Pharma, Hikma, Hikma Farmaceutica, Hisun Pharm Hangzhou, Hospira, Intas Pharms Usa, Novast Labs, Pharmobedient, Pliva Lachema, Qilu Pharm Hainan, Sandoz, Shilpa, Sun Pharma Global, and Teva Pharms Usa. and is included in twenty-six NDAs.

The generic ingredient in IRINOTECAN is irinotecan hydrochloride. There are thirty-three drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the irinotecan hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Irinotecan

A generic version of IRINOTECAN was approved as irinotecan hydrochloride by ACTAVIS TOTOWA on February 27^th, 2008.

Start Trial

AI Deep Research

Questions you can ask:

What is the 5 year forecast for IRINOTECAN?
What are the global sales for IRINOTECAN?
What is Average Wholesale Price for IRINOTECAN?

Summary for IRINOTECAN

US Patents:	0
Applicants:	23
NDAs:	26
Drug Prices:	Drug price information for IRINOTECAN
DailyMed Link:	IRINOTECAN at DailyMed

Drug patent expirations by year for IRINOTECAN

US Patents and Regulatory Information for IRINOTECAN

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pliva Lachema	IRINOTECAN HYDROCHLORIDE	irinotecan hydrochloride	INJECTABLE;INJECTION	078122-001	Oct 31, 2008		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Hospira	IRINOTECAN HYDROCHLORIDE	irinotecan hydrochloride	INJECTABLE;INJECTION	077915-001	Feb 27, 2008	AP	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Sandoz	IRINOTECAN HYDROCHLORIDE	irinotecan hydrochloride	INJECTABLE;INJECTION	090137-002	Nov 12, 2009		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Qilu Pharm Hainan	IRINOTECAN HYDROCHLORIDE	irinotecan hydrochloride	INJECTABLE;INJECTION	203380-003	May 3, 2016	AP	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Shilpa	IRINOTECAN HYDROCHLORIDE	irinotecan hydrochloride	INJECTABLE;INJECTION	208718-001	Dec 28, 2018	AP	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

DrugChatter Q&A for IRINOTECAN

Is Irinotecan effective for CRC?

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.